Have a feature idea you'd love to see implemented?
Let us know!
MYGN Myriad Genetics Inc
Price (delayed)
$26.43
Market cap
$2.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.79
Enterprise value
$2.45B
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing
Highlights
The EPS has grown by 41% YoY and by 36% from the previous quarter
The company's net income rose by 37% YoY and by 34% QoQ
The quick ratio has increased by 36% year-on-year but it has declined by 5% since the previous quarter
The company's equity fell by 2.6% QoQ
Key stats
What are the main financial stats of MYGN
Market
Valuations
Earnings
Shares outstanding
90.82M
Market cap
$2.4B
Enterprise value
$2.45B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.23
Price to sales (P/S)
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
Revenue
$802.2M
EBIT
-$153.4M
EBITDA
-$83.5M
Free cash flow
-$141.3M
Per share
Balance sheet
Liquidity
EPS
-$1.79
Free cash flow per share
-$1.56
Book value per share
$8.18
Revenue per share
$8.85
TBVPS
$5.29
Total assets
$1.09B
Total liabilities
$344.6M
Debt
$143.3M
Equity
$740.5M
Working capital
$142.7M
Debt to equity
0.19
Current ratio
1.96
Quick ratio
1.44
Net debt/EBITDA
-0.61
Margins
Efficiency
Dividend
EBITDA margin
-10.4%
Gross margin
69.1%
Net margin
-19.3%
Operating margin
-19.4%
Return on assets
-13.8%
Return on equity
-20.9%
Return on invested capital
-39.2%
Return on capital employed
-16.4%
Return on sales
-19.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MYGN stock price
How has the Myriad Genetics stock price performed over time
Intraday
-1.97%
1 week
0.76%
1 month
-3.75%
1 year
71.07%
YTD
38.09%
QTD
-3.5%
Financial performance
How have Myriad Genetics's revenue and profit performed over time
Revenue
$802.2M
Gross profit
$554M
Operating income
-$155.9M
Net income
-$155.2M
Gross margin
69.1%
Net margin
-19.3%
The company's operating margin rose by 48% YoY and by 36% QoQ
The net margin has grown by 46% YoY and by 36% from the previous quarter
The operating income rose by 41% YoY and by 33% QoQ
The company's net income rose by 37% YoY and by 34% QoQ
Growth
What is Myriad Genetics's growth rate over time
Valuation
What is Myriad Genetics stock price valuation
P/E
N/A
P/B
3.23
P/S
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
The EPS has grown by 41% YoY and by 36% from the previous quarter
MYGN's price to book (P/B) is 62% higher than its 5-year quarterly average of 2.0 and 35% higher than its last 4 quarters average of 2.4
The company's equity fell by 2.6% QoQ
The P/S is 30% higher than the last 4 quarters average of 2.3 and 19% higher than the 5-year quarterly average of 2.5
Myriad Genetics's revenue has increased by 15% YoY and by 3.6% QoQ
Efficiency
How efficient is Myriad Genetics business performance
The ROS has grown by 49% YoY and by 36% from the previous quarter
MYGN's return on equity is up by 34% since the previous quarter and by 29% year-on-year
Myriad Genetics's return on assets has increased by 34% YoY and by 32% QoQ
The return on invested capital has grown by 32% since the previous quarter and by 30% year-on-year
Dividends
What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MYGN.
Financial health
How did Myriad Genetics financials performed over time
Myriad Genetics's current ratio has increased by 47% YoY
The quick ratio has increased by 36% year-on-year but it has declined by 5% since the previous quarter
The debt is 81% less than the equity
The debt to equity is down by 32% year-on-year
The debt has contracted by 30% YoY and by 2.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.